NEW YORK, NY / ACCESSWIRE / August 19, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.

Home Point Capital Inc. (NASDAQ:HMPT)

If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/home-point-capital-inc-loss-submission-form?prid=18701&wire=1
Lead Plaintiff Deadline: August 20, 2021
This lawsuit is on behalf of all persons and entities other than Defendants that purchased or otherwise acquired Home Point common stock pursuant and/or traceable to the Company's January 29, 2021 initial public offering.

Allegations against HMPT include that: (i) Home Point's aggressive expansion of its broker partners would dramatically increase the Company's expenses; (ii) the mortgage industry was anticipating industry-wide decreased gain-on-sale margins as a result of rising interest rates in 2021 and Home Point would be subject to the same competitive pressures; (iii) accordingly, the Company had overstated its business and financial prospects; and (iv) as a result, the Offering Documents were materially false and/or misleading and failed to state information required to be stated therein.

Iterum Therapeutics Plc (NASDAQ:ITRM)

If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/iterum-therapeutics-plc-loss-submission-form?prid=18701&wire=1
Lead Plaintiff Deadline: October 4, 2021
Class Period: November 30, 2020 - July 23, 2021

Allegations against ITRM include that: (i) the sulopenem New Drug Application ("NDA") lacked sufficient data to support approval for the treatment of adult women with urinary tract infections caused by designated susceptible microorganisms proven or strongly suspected to be nonsusceptible to a quinolone; (ii) accordingly, it was unlikely that the Food and Drug Administration would approve the sulopenem NDA in its current form; (iii) Defendants downplayed the severity of issues and deficiencies associated with the sulopenem NDA; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Selectquote, Inc. (NYSE:SLQT)

If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/selectquote-inc-loss-submission-form?prid=18701&wire=1
Lead Plaintiff Deadline: October 15, 2021
Class Period: February 8, 2021 - May 11, 2021

Allegations against SLQT include that: (1) SelectQuote's 2019 cohort was underperforming; (2) as a result, the Company's financial results would be adversely impacted; and (3) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

To learn more contact Vincent Wong, Esq. either via email vw@wongesq.com or by telephone at 212.425.1140.

Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

SOURCE: The Law Offices of Vincent Wong